ID 110581
Title Transcription
トウカ ニオケル Stage IVb スイガン ノ チリョウ セイセキ
Title Alternative
Evaluation and treatment of Stage IVb pancreatic cancer
Author
Miyamoto, Hidenori Department of Digestive and Pediatric Surgery, The University of Tokushima School of Medicine
Kurita, Nobuhiro Department of Digestive and Pediatric Surgery, The University of Tokushima School of Medicine KAKEN Search Researchers
Miyake, Hidenori Department of Digestive and Pediatric Surgery, The University of Tokushima School of Medicine
Fujii, Masahiko Department of Digestive and Pediatric Surgery, The University of Tokushima School of Medicine
Sasaki, Katsuya Department of Digestive and Pediatric Surgery, The University of Tokushima School of Medicine
Takagi, Toshihide Department of Digestive and Pediatric Surgery, The University of Tokushima School of Medicine
Takamura, Kazuhito Department of Digestive and Pediatric Surgery, The University of Tokushima School of Medicine
Morine, Yuuji Department of Digestive and Pediatric Surgery, The University of Tokushima School of Medicine Tokushima University Educator and Researcher Directory KAKEN Search Researchers
Imura, Satoru Department of Digestive and Pediatric Surgery, The University of Tokushima School of Medicine Tokushima University Educator and Researcher Directory KAKEN Search Researchers
Tashiro, Seiki Department of Digestive and Pediatric Surgery, The University of Tokushima School of Medicine Tokushima University Educator and Researcher Directory
Keywords
Stage IVb pancreatic cancer
prognostic factor
hepatic metastasis
treatment
somatostatin analog
Content Type
Journal Article
Description
Pancreatic cancer is often detected in a far advanced stage and the prognosis is still extremely poor. A clinicopathological study was made on 49 patients with Stage IVb pancreatic cancer treated at our department from March 1994 to February 2002. In this study, patient factors (age and gender), tumor factors (hepatic metastasis, peritoneal dissemination, and distant metastasis), and treatment factors (systemic chemotherapy, intra- and postoperative radiotherapy, some treatments to hepatic metastasis, and surgical resection) were examined, and the survival was evaluated statistically. Overall mean survival was 150 days and the 1-year survival rate was 0%. With multivariate analysis, prognostic factors were hepatic metastasis, peritoneal dissemination and some treatments to hepatic metastasis. In advanced pancreatic cancer with hepatic metastasis, the prognostic factor was just some treatments to hepatic metastasis. Systemic chemotherapy with somatostatin analog was ineffective. At present we use either gemcitabine or 5FU in systemic chemotherapy for Stage IVb pancreatic cancers without hepatic metastasis, and conduct hepatic arterial infusion therapy for those with hepatic metastasis.
Journal Title
四国医学雑誌
ISSN
00373699
NCID
AN00102041
Publisher
徳島医学会
Volume
59
Issue
1-2
Start Page
30
End Page
34
Sort Key
30
Published Date
2003-04-25
EDB ID
FullText File
language
jpn
TextVersion
Publisher
departments
Medical Sciences
University Hospital